Quarterly report pursuant to Section 13 or 15(d)

Note J - Common Stock and Earnings Per Share

v3.22.2
Note J - Common Stock and Earnings Per Share
6 Months Ended
Jul. 02, 2022
Notes to Financial Statements  
Earnings Per Share [Text Block]

NOTE J – COMMON STOCK AND EARNINGS PER SHARE

 

Basic earnings per share (“EPS”) is based on the weighted-average number of shares outstanding for each period. Shares that have been repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that are outstanding for the calculation of basic EPS based on the time they were outstanding in any period. Diluted EPS is based on shares that are outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that are included in the diluted EPS calculations under the treasury stock method include equity awards that are in-the-money but have not yet been exercised.

 

The following is a reconciliation of the numerator and denominator used to calculate basic EPS and diluted EPS for the periods indicated:

 

                                 
   

Quarter Ended

   

Six Months Ended

 
   

July 2,

   

July 3,

   

July 2,

   

July 3,

 
   

2022

   

2021

   

2022

   

2021

 

Net earnings available to common shareholders

  $ 19,157     $ 38,234     $ 41,626     $ 68,855  

Weighted average common shares outstanding - basic

    19,215       20,247       19,283       20,570  

Dilutive effect of in-the-money equity awards

    29       199       79       201  

Weighted average common shares outstanding - diluted

    19,244       20,446       19,362       20,771  

Earnings per common share from net earnings - basic

  $ 1.00     $ 1.89     $ 2.16     $ 3.35  

Earnings per common share from net earnings - diluted

  $ 1.00     $ 1.87     $ 2.15     $ 3.31  

 

Equity awards for the following shares were not included in the computation of diluted EPS due to the fact that their effect would be anti-dilutive: 

 

                                 
   

Quarter Ended

   

Six Months Ended

 
   

July 2,

   

July 3,

   

July 2,

   

July 3,

 
   

2022

   

2021

   

2022

   

2021

 
      374       59       272       58  

 

There were no shares repurchased during the three months ended July 2, 2022. During the three months ended  July 3, 2021, the Company repurchased and retired 304 shares for $29,701 under the Company's share repurchase plan.

 

During the six months ended July 2, 2022 and July 3, 2021, the Company repurchased and retired 288 shares and 1,025 shares for $25,382 and $99,155, respectively, under the Company’s share repurchase plan. The excess of the repurchase price over par value is allocated between additional paid-in capital and retained earnings on a pro-rata basis. The purchase of shares under this plan reduces the number of shares outstanding in the above calculations.

 

As of  July 2, 2022, the remaining authorized repurchase amount under the stock repurchase plan was $82,839. There is no expiration date on the remaining approved repurchase amount and no requirement for future share repurchases. 

 

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)